BTK and mantle cell lymphoma: In effort to develop small molecule agents which act against MCL, we designed a series of thienopyranone (TP)-based compounds with the ability to concomitantly bind bromodomains (BDs) of BRD4, the catalytic domain of BTK, and the catalytic domain of PI3K.